Cellestia

News

2024

January 2024

Cellestia awarded Innosuisse Grant to advance GvHD prevention therapy

Read more

2023

August 2023

Cellestia’s publication “The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer” is out in Cancers

Read more

June 2023

A new IIT Phase II trial is now open for patient recruitment at Dana-Farber Cancer Institute

Read more

May 2023

The Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of rr/r-T-ALL patients is now open for recruitment

Read more

May 2023

CB-103 treatment in metastatic clear cell renal cell carcinoma shows promising results

Read more

2022

June 2022

A case study shows contribution of Cellestia ’s CB-103 in achieving complete response in a relapse/refractor T-ALL patient

Read more

2021

December 2021

CB-103 has been granted an Orphan Designation for the treatment of Acute Lymphoblastic Leukaemia (ALL)

Read more

November 2021

Cellestia presented its poster at SOHC – Swiss Oncology and Hematology Congress

Read more

July 2021

Cellestia’s new lab opening at Superlab, Lausanne

Read more

June 2021

Cellestia at the “Transcription Factor Drug Development Virtual Congress”

Read more

June 2021

Michael Bauer Interview at PharmaBoardroom

Read more

June 2021

Cellestia presents Phase 1 clinical results at ASCO 2021

Read more

May 2021

Nature Reviews Drug Discovery Article “Advances in targeting ‘undruggable’ transcription factors with small molecules”

Read more

March 2021

Cellestia CEO, Michael Bauer at StartUpTicker.ch

Read more

March 2021

Cellestia’s article in Nature Biopharma Deal Makers

Read more

February 2021

Cellestia has received the Innosuisse Certificate

Read more

2020

December 2020

Cellestia launches a new drug discovery program to target Transcription Factors

Read more

October 2020

Article in “The Swiss Startup Ecosystem: Innovation in Chemistry and the Life Sciences”

Read more

September 2020

Cellestia presented promising clinical data of its lead compound CB-103 at ESMO 2020

Read more

August 2020

Cellestia announces appointment of Florian D. Vogl, MD, PhD as Chief Medical Officer

Read more

August 2020

Gaudenz Von Capeller at the LifeSci Partners Summer Symposium

Read more

July 2020

PNAS Article

Read more

June 2020

Michael Bauer at BZBasel: how Cellestia manages COVID-19

Read more

2019

December 2019

Successful closing of Series B financing round with CHF 20M

Read more
Most innovative Swiss Start-up Award

November 2019

Most innovative Swiss Start-up Award – November 2019

Read more

October 2019

Autumn 2019 News

Read more

July 2019

New Board Members named

Read more

June 2019

9th International Conference – NOTCH Targeting in Cancer

Read more

February 2019

IND accepted by the FDA

Read more